Researchers at the University of Georgia and Sanofi Pasteur, the vaccines division of Sanofi, announced today the development of a vaccine that protects against multiple strains of both seasonal and pandemic H1N1 influenza in mouse models.
They published their findings recently in the Journal of Virology.
Researchers from UGA and Sanofi Pasteur, which has a research and development collaboration agreement with UGA, will present their data tomorrow, March 30, at the World Vaccine Congress US 2016 in Washington, D.C.
“One of the problems with current influenza vaccines is that we have to make predictions about which virus strains will be most prevalent every year and build our vaccines around those predictions,” said Ted Ross, director of UGA’s Center for Vaccines and Immunology and Georgia Research Alliance Eminent Scholar in Infectious Diseases in the College of Veterinary Medicine. “What we have developed is a vaccine that protects against multiple different strains of H1N1 virus at once, so we might be able to one day replace the current standard of care with this more broadly cross-protective vaccine.”
The H1N1 influenza virus caused a worldwide pandemic in 2009. When it was first detected, it was called swine flu because the virus was similar to those found in pigs, but the virus now circulates as a seasonal form of influenza.
Using a technique called Computationally Optimized Broadly Reactive Antigen, or COBRA, UGA researchers Donald Carter, Christopher Darby and Bradford Lefoley, along with Ross, created nine prototype synthetic compound vaccines constructed using genetic sequences from multiple influenza virus strains.
The COBRA vaccines were designed to recognize H1N1 viruses isolated within the last 100 years, but many of the experimental vaccines produced immunity against influenza strains not included in the design. This means that scientists may be able to produce a vaccine that not only protects against recognized seasonal and pandemic influenza strains, but also strains that have yet to be discovered.
Because this vaccine is generated from the genetic sequences of multiple flu viruses, it may protect against many strains over several years, Ross said. That would also allow for year-round manufacturing of the vaccine, since scientists would not have to halt production every year to identify the most prevalent strains.
This research is part of a broader effort to create a universal influenza vaccine, which would protect against all strains of the virus.
“We still have some work to do before we get a truly universal flu vaccine,” Ross said. “But the COBRA vaccine we’ve developed for H1N1 virus subtypes is a major step in the right direction.”
The Latest on: Flu vaccine
via Google News
The Latest on: Flu vaccine
- New Deer Show committee member quits over equine flu vaccine row on April 17, 2019 at 10:20 pm
A row has broken out over plans to ban horses from a north-east agricultural show – unless they have been given a vaccination at least the week before. The New Deer Show is one of the north-east’s ... […]
- Labor calls on Tasmanian government to release winter plan, as influenza cases increase on April 17, 2019 at 8:00 pm
Labor is calling on the state government to reveal details of how it plans to deal with increased demand on hospitals during flu season. So far this year there have been 448 of reported cases of ... […]
- Health officials considering introducing ‘double jab’ of flu vaccine to combat horror season on April 17, 2019 at 8:00 pm
HEALTH officials are considering implementing a “double jab” of the flu vaccine to combat a horror season for influenza in the Far North. Cairns Hospital has set a target to vaccinate up to 80 per ... […]
- Grant could bring lifetime flu vaccine on April 17, 2019 at 5:41 pm
Since 1984, a non-profit organization called TED, short for Technology, Entertainment and Design has helped spread groundbreaking ideas around the globe. A subsidiary of TED donated a lot of money to ... […]
- Influenza Medication Market Analysis & Forecast 2019| Daiichi Sankyo Company, GlaxoSmithKline, Natco Pharma, F. Hoffmann-La Roche on April 17, 2019 at 4:05 pm
The report on the global Influenza Medication market is comprehensively prepared with main focus on the competitive landscape, geographical growth, segmentation, and market dynamics, including drivers ... […]
- Five more people die from influenza in San Diego this season on April 17, 2019 at 3:42 pm
SAN DIEGO (KGTV) — Five more people died from the flu in San Diego last week. The new deaths, ranging in people aged from 47- to 77-years-old, all had underlying health conditions, according to the ... […]
- Artikel-artikel mengenai Flu vaccine 2019 on April 17, 2019 at 1:25 pm
The 2018 flu season was mild, while 2017 was a particularly bad year. It's impossible to predict what the 2019 flu season has in store, but we've seen more cases so far this year than usual. […]
- UW researchers developing permanent flu vaccine score $45M donation on April 17, 2019 at 12:49 pm
The donation comes from The Audacious Project, an organization that looks to fund projects that can effect positive change on a global scale. UW’s Institute for Protein Design certainly seems to ... […]
- $12 million grant renewal for flu vaccine research on April 17, 2019 at 10:18 am
The National Institutes of Health has awarded the Stanford Institute for Immunity, Transplantation and Infection a five-year, $12 million renewal of a grant for the study of how people respond to ... […]
- Swine Influenza Vaccines 2019 Global Trends, Market Size, Share, Status, SWOT Analysis and Forecast to 2025 on April 17, 2019 at 12:42 am
The global Swine Influenza Vaccines market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to ... […]
via Bing News